GeoVax Labs Ownership

GOVX Stock  USD 1.42  0.08  5.33%   
The market capitalization of GeoVax Labs is $14.15 Million. Roughly 91.21 (percent) of GeoVax Labs outstanding shares are held by general public with 0.47 % owned by insiders and only 8.32 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2000-03-31
Previous Quarter
2.5 M
Current Value
6.4 M
Avarage Shares Outstanding
719.4 K
Quarterly Volatility
1.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as GeoVax Labs in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of GeoVax Labs, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GeoVax Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy GeoVax Stock please use our How to Invest in GeoVax Labs guide.

GeoVax Stock Ownership Analysis

The company has price-to-book (P/B) ratio of 1.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. GeoVax Labs recorded a loss per share of 8.39. The entity last dividend was issued on the 25th of September 2020. The firm had 1:15 split on the 31st of January 2024. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia. Geovax Labs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To learn more about GeoVax Labs call the company at (678) 384-7220 or check out https://www.geovax.com.
Besides selling stocks to institutional investors, GeoVax Labs also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different GeoVax Labs' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align GeoVax Labs' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

GeoVax Labs Quarterly Liabilities And Stockholders Equity

11.11 Million

Less than 1% of GeoVax Labs are currently held by insiders. Unlike GeoVax Labs' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against GeoVax Labs' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of GeoVax Labs' insider trades

GeoVax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as GeoVax Labs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GeoVax Labs backward and forwards among themselves. GeoVax Labs' institutional investor refers to the entity that pools money to purchase GeoVax Labs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Ifs Advisors, Llc2024-12-31
300
Wells Fargo & Co2024-12-31
134
Morgan Stanley - Brokerage Accounts2024-12-31
120
Bank Of America Corp2024-12-31
77.0
Alphamark Advisors, Llc2024-09-30
50.0
Headlands Technologies Llc2024-12-31
50.0
Royal Bank Of Canada2024-12-31
4.0
Fmr Inc2024-12-31
1.0
Tower Research Capital Llc2024-12-31
0.0
Geode Capital Management, Llc2024-12-31
90.1 K
Vanguard Group Inc2024-12-31
51.1 K
Note, although GeoVax Labs' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

GeoVax Labs Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeoVax Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeoVax Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GeoVax Labs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

GeoVax Labs Outstanding Bonds

GeoVax Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GeoVax Labs uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GeoVax bonds can be classified according to their maturity, which is the date when GeoVax Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for GeoVax Stock Analysis

When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.